(N- Ac- His(1)- Nle(17)- Arg(20,21)- Ala(26))- vasoactive intestinal peptide

amino acid sequence given in first source

Also Known As:

vasoactive intestinal peptide, (N-Ac-His(1)-Nle(17)-Arg(20,21)-Ala(26))-; (N-acetyl-histidyl(1)-norleucyl(17)-arginyl(20,21)-alanine(26))-VIP; VIP-a

Networked: 35 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Said, Sami I: 2 articles (07/2014 - 03/2007)
2.	Hamidi, Sayyed A: 2 articles (01/2013 - 03/2007)
3.	Szema, Anthony M: 2 articles (01/2013 - 03/2007)
4.	Delgado, Mario: 2 articles (11/2007 - 12/2006)
5.	Gonzalez-Rey, Elena: 2 articles (11/2007 - 12/2006)
6.	Ahmad, Tariq: 1 article (01/2022)
7.	Alexander, James L: 1 article (01/2022)
8.	Altmann, Daniel M: 1 article (01/2022)
9.	Anandabaskaran, Sulak: 1 article (01/2022)
10.	Balarajah, Sharmili: 1 article (01/2022)

Related Diseases

1.	Heart Failure 12/01/2003 - "Vasoactive intestinal peptide (VIP): a new neuroendocrine marker of clinical progression in chronic heart failure?" 05/01/2000 - "The aim of our study was to investigate the pathophysiological role of the vasoactive intestinal peptide (VIP), a vasodilating neuropeptide with positive inotropic and chronotropic properties, in heart failure. " 09/25/1998 - "Angiotensin converting enzyme may also metabolise vasoactive intestinal peptide (VIP), a vasodilator and positive inotrope whose concentration in the heart declines in heart failure. "
2.	Vision Disorders (Hemeralopia) 04/01/1998 - "The use of eye care services by people with and without diabetes was investigated in the Melbourne Visual Impairment Project (VIP), a population based study of eye disease in a representative sample of Melbourne residents 40 years of age and older. " 04/01/1998 - "All subjects were participants in the Melbourne Visual Impairment Project (Melbourne VIP), a population-based prevalence study of eye disease that included residential and nursing home populations. "
3.	Eye Diseases (Eye Disease) 04/01/1998 - "The use of eye care services by people with and without diabetes was investigated in the Melbourne Visual Impairment Project (VIP), a population based study of eye disease in a representative sample of Melbourne residents 40 years of age and older. " 04/01/1998 - "All subjects were participants in the Melbourne Visual Impairment Project (Melbourne VIP), a population-based prevalence study of eye disease that included residential and nursing home populations. "
4.	Chagas Disease (American Trypanosomiasis) 10/01/2013 - "In this context, our study was designed to determine the expression of vasoactive intestinal peptide (VIP), a neuropeptide with anti-inflammatory properties, in blood from the indeterminate and cardiac polarized forms of Chagas disease. "
5.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2017 - "Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial."

Related Drugs and Biologics

1.	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
2.	Neuropeptides
3.	Gemcitabine
4.	vandetanib (ZD6474)
5.	Vasodilator Agents (Vasodilators)
6.	COVID-19 Vaccines
7.	Norleucine
8.	Peptide Hormones (Polypeptide Hormones)
9.	Neurokinin-2 Receptors (Neurokinin 2 Receptor)
10.	Vaccines

Related Therapies and Procedures

1.	Vocational Rehabilitation
2.	Home Nursing (Nursing, Home)
3.	Glycemic Control